Richard G Gregory

US Patent:

59817143, Nov 9, 1999

Filed:

Aug 15, 1996

Appl. No.:

8/691605

Inventors:

Seng H. Cheng - Bosaton MA
John Marshall - Milford MA
Richard J. Gregory - Ayer MA
Patrick W. Rafter - Natick MA

Assignee:

Genzyme Corporation - Cambridge MA

International Classification:

C07K 1628
C12N 518

US Classification:

5303882

Abstract:

Antibodies for binding epitopes of cystic fibrosis transmembrane conductance regulator (CFTR) and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting CFTR in a biological sample and/or in a method for purifying CFTR from an impure solution. In addition, the present invention includes a method for detecting CFTR in a biological sample from a nonhuman cystic fibrosis knockout animal wherein the the nonhuman cystic fibrosis knockout animal has been subjected to human CFTR replacement therapy. Another aspect of the present invention is a method for determining the orientation of CFTR in the membrane of a lipid vesicle. Yet another aspect of the invention is a kit for detecting CFTR in a biological sample.

US Patent:

20220195026, Jun 23, 2022

Filed:

Dec 23, 2021

Appl. No.:

17/561510

Inventors:

- Paris, FR
Kevin Brower - Holliston MA, US
Patrick Finn - Franklin MA, US
Richard C. Gregory - Framingham MA, US
Rao Koduri - Shrewsbury MA, US
Feng Liu - San Diego CA, US
Natalia Malkova - Needham MA, US
Parminder Mankoo - Foster City CA, US
Jack R. Pollard - Acton MA, US
Huawei Qiu - Westborough MA, US
Joachim Theilhaber - Cambridge MA, US
Christopher Winter - Swampscott MA, US
Marcella Yu - Fremont CA, US

Assignee:

SANOFI - Paris

International Classification:

C07K 16/22
A61P 35/00
C07K 16/28
C07K 16/30
C07K 16/32

Abstract:

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

US Patent:

20200399358, Dec 24, 2020

Filed:

Jul 16, 2020

Appl. No.:

16/931198

Inventors:

- Paris, FR
Kevin Brower - Holliston MA, US
Patrick Finn - Franklin MA, US
Richard C. Gregory - Framingham MA, US
Rao Koduri - Shrewsbury MA, US
Feng Liu - San Diego CA, US
Natalia Malkova - Needham MA, US
Parminder Mankoo - Foster City CA, US
Jack R. Pollard - Acton MA, US
Huawei Qiu - Westborough MA, US
Joachim Theilhaber - Cambridge MA, US
Christopher Winter - Swampscott MA, US
Marcella Yu - Fremont CA, US

International Classification:

C07K 16/22
A61P 35/00
C07K 16/28
C07K 16/30
C07K 16/32

Abstract:

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.

US Patent:

20180244763, Aug 30, 2018

Filed:

Jan 19, 2018

Appl. No.:

15/875532

Inventors:

- Paris, FR
Kevin Brower - Holliston MA, US
Patrick Finn - Franklin MA, US
Richard C. Gregory - Framingham MA, US
Rao Koduri - Shrewsbury MA, US
Feng Liu - San Diego CA, US
Natalia Malkova - Needham MA, US
Parminder Mankoo - Foster City CA, US
Jack R. Pollard - Acton MA, US
Huawei Qiu - Westborough MA, US
Joachim Theilhaber - Cambridge MA, US
Christopher Winter - Swampscott MA, US
Marcella Yu - Fremont CA, US

Assignee:

SANOFI - Paris

International Classification:

C07K 16/22
C07K 16/30
C07K 16/28
A61P 35/00

Abstract:

The invention provides an improved pan-TGF-β antibody for treatment of conditions that are mediated by TGF-β, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.